Pharmafile Logo

asciminib

Novartis building

FDA deems Novartis lung cancer drug a “breakthrough therapy”

LDK378 will have accelerated passage through development

- PMLiVE

Bayer fails to overturn Nexavar compulsory licence in India

Natco Pharma allowed to sell cut-price version of cancer drug

- PMLiVE

Roche gains EU approval for Perjeta in breast cancer

Available in combination with Herceptin and docetaxel chemotherapy

Novartis building

Novartis’ Ilaris cleared for gouty arthritis in EU

First biologic drug approved for condition in Europe

- PMLiVE

Novartis provides multimedia support to Rare Diseases Day

Collaborates with Eurordis on multimedia education campaign

Novartis to expand SMS for Life approach across Africa

Will broaden reach of mobile-based medicines management programme 

- PMLiVE

Novartis gives Vasella honorary role as payout row continues

Named honorary chairman chairman at Swiss pharma firm after stepping down as chairman

Roche - Basel

Roche’s Herceptin follow-up cleared in US

FDA approval for Kadcyla (formerly T-DM1) in breast cancer

- PMLiVE

Late-stage failure for Merck’s cilengitide in brain cancer

Integrin inhibitor unable to improve overall survival in phase III trials

- PMLiVE

Novartis, Roche under scrutiny in Italy on Avastin/Lucentis collusion claims

Antitrust authorities in Italy open investigation into the pharma companies

Novartis building

Novartis’ Zortress cleared by FDA for liver transplants

Adds to kidney transplant indication in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links